EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Nintedanib in children and adolescents with fibrosing interstitial lung diseases

Robin Deterding, Lisa R Young, Emily M DeBoer, David Warburton, Steven Cunningham, Nicolaus Schwerk, Kevin R Flaherty, Kevin K Brown, Mihaela Dumistracel, Elvira Erhardt iD, Julia Bertulis, Martina Gahlemann und 3 weitere

European Respiratory Journal · 2023-02 · 61 (2) · 2201512

DOI: 10.1183/13993003.01512-2022 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, online erschienen am 30.08.2022. Verfasst von Robin Deterding und 14 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pediatric Pulmonary and Sleep Medicine, Department of Pediatrics, University of Colorado Denver, Denver, CO, USA. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Childhood interstitial lung disease (ILD) comprises a spectrum of rare ILDs affecting infants, children and adolescents. Nintedanib is a licensed treatment for pulmonary fibrosis in adults. The primary objectives of the InPedILD trial were to determine the dose-exposure and safety of nintedanib in children and adolescents with fibrosing ILD.

Methods

Patients aged 6–17 years with fibrosing ILD on high-resolution computed tomography and clinically significant disease were randomised 2:1 to receive nintedanib or placebo for 24 weeks and then open-label nintedanib. Dosing was based on weight-dependent allometric scaling. Co-primary end-points were the area under the plasma concentration–time curve at steady state (AUC τ,ss ) at weeks 2 and 26 and the proportion of patients with treatment-emergent adverse events at week 24.

Results

26 patients received nintedanib and 13 patients received placebo. The geometric mean (geometric coefficient of variation) AUC τ,ss for nintedanib was 175 µg·h·L −1 (85.1%) in patients aged 6–11 years and 167 µg·h·L −1 (83.6%) in patients aged 12–17 years. In the double-blind period, adverse events were reported in 84.6% of patients in each treatment group. Two patients discontinued nintedanib due to adverse events. Diarrhoea was reported in 38.5% and 15.4% of the nintedanib and placebo groups, respectively. Adjusted mean± se changes in percentage predicted forced vital capacity at week 24 were 0.3±1.3% in the nintedanib group and −0.9±1.8% in the placebo group.

Conclusions

In children and adolescents with fibrosing ILD, a weight-based dosing regimen resulted in exposure to nintedanib similar to adults and an acceptable safety profile. These data provide a scientific basis for the use of nintedanib in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialIdiopathic Pulmonary FibrosisAdultHumansAdolescentChildDisease ProgressionFibrosisVital CapacityDouble-Blind MethodIndoles

Substanzen

nintedanibIndoles

Autor:innen und Institutionen

  • Section of Pediatric Pulmonary and Sleep Medicine, Department of Pediatrics, University of Colorado Denver, Denver, CO, USA.
  • The Children's Hospital Colorado, Aurora, CO, USA.
  • These two authors contributed equally.
  • Division of Pulmonary and Sleep Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

ORCID-Profile: Elvira Erhardt

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Deterding, R., Young, L. R., DeBoer, E. M., Warburton, D., Cunningham, S., Schwerk, N., Flaherty, K. R., Brown, K. K., Dumistracel, M., Erhardt, E., Bertulis, J., Gahlemann, M., Stowasser, S., Griese, M., & InPedILD trial investigators (2023). Nintedanib in children and adolescents with fibrosing interstitial lung diseases. European Respiratory Journal, 61(2), 2201512. https://doi.org/10.1183/13993003.01512-2022

Vancouver

Deterding R, Young LR, DeBoer EM, Warburton D, Cunningham S, Schwerk N, et al. Nintedanib in children and adolescents with fibrosing interstitial lung diseases. European Respiratory Journal. 2023;61(2):2201512. doi:10.1183/13993003.01512-2022

BibTeX
@article{Deterding2023,
  author = {Deterding, Robin and Young, Lisa R and DeBoer, Emily M and Warburton, David and Cunningham, Steven and Schwerk, Nicolaus and Flaherty, Kevin R and Brown, Kevin K and Dumistracel, Mihaela and Erhardt, Elvira and Bertulis, Julia and Gahlemann, Martina and Stowasser, Susanne and Griese, Matthias and InPedILD trial investigators, InPedILD trial investigators},
  title = {Nintedanib in children and adolescents with fibrosing interstitial lung diseases},
  journal = {European Respiratory Journal},
  year = {2023},
  volume = {61},
  number = {2},
  pages = {2201512},
  doi = {10.1183/13993003.01512-2022}
}
Kostenlos starten →